Elevai Labs Inc., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, announces Evolve Medical Inc. as the exclusive distributor of Elevai Skincare products in Canada. The Elevai E-Series product range, a pre-and post-procedure skincare system developed with a proprietary stem cell exosome technology, will now be available to dermatologists and plastic surgeons throughout Canada. 

Elevaiโ€™s expansion into Canada taps into the $6 billion North American physician dispensed cosmeceuticals market size, according to company officials. Industry numbers and trends for Canada typically run parallel to those of the U.S. at a tenth of the scale, indicating robust opportunities in this new market.

Evolve Medical CEO Sharon Clarke says, โ€œAfter 35 years in cosmetic dermatology and skincare, Iโ€™ve been fortunate to launch products like Juvรฉderm 1 and Botox Cosmetic2 in Canada as well as bringing best-in-class medical skincare products including ZO Skin Health and skinbetter science to Canada. Iโ€™ve been waiting for a series of products that will not only take us to a new level in anti-aging but will also change the way we think about aging. Elevai is about to change our world.โ€

The key ingredient in Elevai products is the patent-pending Elevai Exosome technology, company officials say. As exosomes penetrate the skin, they mimic the bodyโ€™s natural healing responses. 

Skin damage and extrinsic aging caused by exposure to daily aggressors like pollution and UVA/UVB can benefit from exosomes, supporting improved blood flow as well as promoting collagen and elastin production to reveal rejuvenated skin from the inside out, according to Elevai officials.